Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Episodic and Chronic Cluster Headache: Evaluation of Health-Related Quality of Life Impact and Estimation of Health-state Utilities
Headache
Headache Posters (7:00 AM-5:00 PM)
136
Evaluate the impact of CH attacks on health-related quality of life (HRQOL), work-productivity, and estimate health-state utility (HSU) values in patients with episodic (ECH) or chronic (CCH) CH. 
Cluster headache (CH), is a primary headache disorder composed of recurrent excruciatingly painful headache attacks.
 A cross-sectional survey was administered to patients with ECH or CCH via a United Kingdom based patient group. This survey collected patients’ demographics and responses to the EQ-5D-5-Levels (EQ-5D-5L), the Cluster Headache Quality of Life Scale (CHQ), and the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem-V2.0 (WPAI:SHP). EQ-5D-5L utility index scores were estimated for health-state scenarios (attack free days, attack day-between attacks, and attack day-during attacks), and by CH type. Attack was defined as an individual headache episode, and bout was defined as a period with regularly recurring headache attacks.

A total of 470 patients completed the survey (ECH=287, CCH=178). Patients with ECH experienced 4.0 mean bouts/year (median 2.0) while patients with CCH experienced 15.0 mean bouts/year (median 3.5). CHQ-scores indicated significant HRQOL impact in activities of daily living, pain and anxiety, and  vitality domains (mean [SD], ECH:2.9 [0.9], 3.3 [0.9], and 3.0 [0.8]; CCH:3.0 [0.9], 3.3 [1.0], 3.1 [0. 9]). Responses to the WPAI:SHP show that impairment to work productivity was 34% for patients with ECH and 56% for patients with CCH. For ECH, disutility estimates for an attack day compared with an attack-free day were 0.29 for between attacks and 0.91 for during attacks. For CCH, these estimates were 0.20 and 0.79 respectively. Utility estimates for time during attacks were consistently below 0 (a state worse than death) for both patients with ECH and CCH.
ECH and CCH are associated with diminished HRQOL and work productivity. The health-status impact of living with CH between attacks was worse for patients with CCH than ECH. 
Authors/Disclosures
Antje Tockhorn-Heidenreich
PRESENTER 		Antje Tockhorn-Heidenreich has received personal compensation for serving as an employee of Eli Lilly and Company. An immediate family member of Antje Tockhorn-Heidenreich has received personal compensation for serving as an employee of Evidera. Antje Tockhorn-Heidenreich has received stock or an ownership interest from Eli Lilly and Company . An immediate family member of Antje Tockhorn-Heidenreich has received stock or an ownership interest from PPD.
No disclosure on file
No disclosure on file
No disclosure on file
Russell Nichols Russell Nichols has received personal compensation for serving as an employee of Eli Lilly and Company. Russell Nichols has received stock or an ownership interest from Eli Lilly and Company.
J S. Andrews J Scott Andrews has received personal compensation for serving as an employee of Eli Lilly & Company. J Scott Andrews has received stock or an ownership interest from Eli Lilly & Company.
Peter Goadsby, MD, PhD, FRS (King Abdullah Univeristy of Science and Technology) Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CoolTech LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health LLC. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kallyope. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seaport Therapeutics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr Reddy's. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orion Pharma. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Massachusetts Medical Society. The institution of Dr. Goadsby has received research support from NIHR. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has a non-compensated relationship as a Trustee with Migraine Trust that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Goadsby has a non-compensated relationship as a Trustee with Organisation for Understanding Cluster Headache (UK) that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.